Neovascularization
0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Heidelberg PharmaGermany - Ladenburg
1 programIntravitreal Bevacizumab in Recalcitrant Inflammatory Ocular NeovascularizationN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Heidelberg PharmaIntravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization
Clinical Trials (1)
Total enrollment: 100 patients across 1 trials
NCT00645697Heidelberg PharmaIntravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization
Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization
Start: Jan 2007Est. completion: Mar 2008100 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space